About Matthew Fust
Matthew Fust is a director at Electra Therapeutics.
Matthew Fust reports to the SEC as a director or officer of 9 public companies, including Crinetics Pharmaceuticals (CRNX), Atara Biotherapeutics (ATRA) and Neumora Therapeutics (NMRA).
Matthew Fust first appears on SEC filings in 2007.
Experience
This experience comes from SEC filings. The years are when the filings name Matthew Fust in the role, so the role may have started earlier or lasted longer.
CI
Crinetics Pharmaceuticals, Inc.
Director
2018 – 2026 · Public company (CRNX)
AI
Atara Biotherapeutics, Inc.
Director
2014 – 2026 · Public company (ATRA)
NI
Neumora Therapeutics, Inc.
Director
2023 – 2026 · Public company (NMRA)
UI
Ultragenyx Pharmaceutical Inc.
Director
2014 – 2026 · Public company (RARE)
DI
Dermira, Inc.
Director
2014 – 2020 · Public company (DERM)
MI
Macrogenics Inc.
Director
2014 – 2019 · Public company (MGNX)
OI
Onyx Pharmaceuticals Inc.
EVP & Chief Financial Officer
2009 – 2013 · Public company (ONXX)
JP
Jazz Pharmaceuticals plc
EVP, Chief Financial Officer
2007 – 2008 · Public company (JAZZ)
Key Colleagues at Startups
The people Matthew Fust works with at each company, as listed on that company's latest Form D.
Electra Therapeutics, Inc. · Form D, Oct 30, 2025
BD
Beth Seidenberg, M.D.
Director
TD
Thomas Geninatti, Ph.D.
Director
CD
Carl Gordon, Ph.D.
Director
ND
Nancy Stagliano, Ph.D.
Director
QD
Quehuong (Kathy) Dong, Pharm.D.
President and CEO, director